

# Correction to “Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results”


Can J Hosp Pharm. 2022;75(2):128

DOI: 10.4212/cjhp.v75i2.3285


*Original citation:* Fernández-Cuerva C, del Rio Valencia JC, Bermejo RT. Effectiveness and safety of palbociclib plus endocrine therapy in hormone receptor–positive, HER2-negative metastatic breast cancer: real-world results. *Can J Hosp Pharm.* 2022;75(1):26-33.

In each of the three figures for this article, the horizontal axis showed incorrect units of time. The unit of measure for these data was months, not weeks. Data reported within the text use the correct unit of measure.


The three figures are reproduced here with the correct unit of measure. The article itself has been corrected (see DOI: 10.4212/cjhp.v75i1.3252).



**FIGURE 1.** Progression-free survival of all patients treated with palbociclib.



**FIGURE 2.** Progression-free survival of patients treated with palbociclib as second-line therapy.



**FIGURE 3.** Progression-free survival of patients treated with palbociclib as third-line therapy.